Anal squamous-cell carcinoma (ASCC) is a rare cancer.
Immune checkpoint inhibitors (ICIs) are used as a second-line treatment.
We aimed to analyze the genomic and transcriptomic profiles of ASCC to predict ICI efficacy.
